Doximity Inc Stock Price, News & Analysis

Doximity (NYSE: DOCS) reported strong Q4 FY2025 financial results with total revenues reaching $138.3 million, up 17% year-over-year. The company demonstrated robust cash flow performance, with Q4 operating cash flow increasing 54% to $98.5 million. For fiscal year 2025, Doximity achieved total revenues of $570.4 million, representing 20% year-over-year growth. Net income margins improved significantly to 45.2% in Q4. The company's subscription revenue grew 17% to $131.9 million in Q4. Looking ahead, Doximity provided Q1 FY2026 guidance with expected revenue between $139-140 million and adjusted EBITDA of $71-72 million. For full FY2026, the company projects revenue of $619-631 million and adjusted EBITDA between $333-345 million.

Doximity (NYSE:DOCS), the leading digital platform for U.S. medical professionals, has scheduled its fiscal 2025 fourth quarter and full year financial results announcement for May 15, 2025, after market close. The company will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the results. Investors can access the live audio webcast through the company's Investor Relations page at https://investors.doximity.com/.

Doximity (NYSE: DOCS), the leading digital platform for U.S. medical professionals, has announced its participation in an upcoming investor event. Anna Bryson, the company's CFO, is scheduled to present at the Raymond James 46th Annual Institutional Investors Conference. The presentation will take place on Tuesday, March 4, 2025, at 10:25 a.m. Eastern Time (7:25 a.m. Pacific Time).

Doximity (NYSE: DOCS) has been named 2025 Best in KLAS in the Video Conferencing Platforms segment for the fourth consecutive year. The company received A-level ratings across all categories, including operations, product, relationship, value, culture, and loyalty, based on interviews with over 80 health system leaders.

Doximity's HIPAA-compliant telehealth platform, Doximity Dialer, enables healthcare providers to connect with patients through phone, video, and text while maintaining personal number privacy. The platform features one-click voice and video visits, custom Caller ID, device and language optimization, and seamless transitions between voice and video calls.

Doximity (NYSE: DOCS) reported strong fiscal Q3 2025 results with total revenue of $168.6 million, up 25% year-over-year. The company demonstrated significant profitability improvements with net income of $75.2 million (57% growth) and adjusted EBITDA of $102.0 million (39% growth).

Key operational highlights include over 610,000 unique providers using clinical workflow tools and AI tools growing 60% quarter-over-quarter. The company's newsfeed reached more than one million unique providers.

For Q4 FY2025, Doximity expects revenue between $132.5-133.5 million and adjusted EBITDA of $62.5-63.5 million. The full fiscal year 2025 guidance was updated to revenue of $564.6-565.6 million and adjusted EBITDA of $306.6-307.6 million.

Doximity (NYSE:DOCS), the leading digital platform for U.S. medical professionals, has announced it will release its fiscal 2025 third quarter financial results on February 6, 2025, after market close. The results will cover the period ended December 31, 2024. The company will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial performance. Interested parties can access the live audio webcast through Doximity's Investor Relations page, where a replay will also be available after the call.

Doximity (NYSE: DOCS) released its State of Telemedicine Report, revealing strong support for virtual healthcare among medical professionals and patients. 83% of surveyed physicians want telemedicine to remain permanent in their practice, with 84% highlighting its value for chronic condition management.

The report shows significant benefits: 67% of physicians reported better disease management, rising to 77% among oncologists. 84% noted increased patient satisfaction, and 64% reported improved patient outcomes. From the patient perspective, 78% desire future virtual care access, with 95% of recent telemedicine users reporting maintained or improved care satisfaction.

Doximity (NYSE: DOCS) reported strong fiscal Q2 2025 results with revenue reaching $136.8 million, up 20% year-over-year. The company demonstrated significant financial growth with net income increasing 44% to $44.2 million and adjusted EBITDA growing 41% to $76.1 million. Operating cash flow surged 430% to $68.3 million. The platform achieved record usage with over 600,000 unique active prescribers. For Q3 FY2025, Doximity expects revenue between $152-153 million and adjusted EBITDA of $83-84 million, while updating full-year guidance to revenue of $535-540 million and adjusted EBITDA of $274-279 million.

Doximity (NYSE: DOCS), the leading digital platform for U.S. medical professionals, has announced its participation in the upcoming Jefferies London Healthcare Conference. The company will be represented by Nate Gross, co-founder and chief strategy officer, and Anna Bryson, chief financial officer, who will deliver a presentation on Thursday, November 21, 2024, at 11:30 a.m. GMT (6:30 a.m. ET).